Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

The directive for the Department of Health and Human Services to develop and test new models aimed at lowering drug costs ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

As weight loss medications like Ozempic and Wegovy become increasingly popular, questions arise about whether the nation is approaching pea ...

Goldman has a buy rating and $325.40 price target on CSL's shares. This implies potential upside of 19% for investors over ...

The day that many thought would never come has dawned: the big orange one now presides over the red button as Commander in ...

ASC leaders are optimistic about the future, citing opportunities for growth over the next five years, including the migration of cardiology procedures to ASCs and increasing patient interest.

Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for seniors and people with ...

Many major maladies have been linked to disturbed slumber caused by sleep apnea, high blood pressure, heart problems a ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.